Call text: 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR-ACTION

“Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance”

Call text v. 5.2 of 13/01/2023

Short title: AMR diagnostics and surveillance 2023 (DISTOMOS)

Contents
1. Introduction ................................................................................................................................. 2
2. Aim of the call ............................................................................................................................. 2
   2.1 Topics of the call ................................................................................................................ 3
   2.2 One Health settings ......................................................................................................... 4
   2.3 Type of studies/experimental approaches ..................................................................... 4
3. Application ..................................................................................................................................... 4
   3.1 Eligibility ............................................................................................................................. 4
   3.2 Widening participation ........................................................................................................ 6
   3.3 Submission of joint transnational proposal .................................................................... 7
   3.4 Financial modalities and funding prerequisites .............................................................. 8
       Initial funding committed by each Funding Partner Organisation ....................................... 8
   3.5 Contact persons .................................................................................................................. 9
4. Evaluation ..................................................................................................................................... 9
   4.1 Scoring system ................................................................................................................... 10
   4.2 Proposal evaluation criteria ............................................................................................. 10
   4.3 Ethics and legal requirements .......................................................................................... 11
       4.4 Social and gender equity, cultural sensitivity and economic viability ....................... 12
5. Decision of project to be funded ............................................................................................... 12
6. Reporting requirements and other obligations of JPIAMR grantees ............................................ 12
7. Intellectual Property .................................................................................................................. 13
8. Partner Consortium Agreement ............................................................................................... 13
9. Open access and FAIR data ...................................................................................................... 13
10. General Data Protection Regulation (GDPR) ........................................................................ 15
11. Privacy ...................................................................................................................................... 16
12. Acknowledgements ................................................................................................................ 16
Annex A: National contact persons for each party providing funding ........................................... 17
Annex B: National Rules and Requirements ................................................................................ 19
1. Introduction

Antimicrobial resistance (AMR) affects humans, animals and plants without geographic borders or species barriers. Progress on AMR is necessary to achieve the United Nations (UN) Sustainable Development Goals (SDGs), with AMR being deeply rooted into attainment of SDGs promoting no poverty, good health and wellbeing, zero hunger, reduced inequality, decent work and international growth. The European One Health Action Plan against AMR encourages the EU and its Member States to deliver innovative, effective and sustainable responses to AMR. Addressing the rising threat of antimicrobial resistance (AMR) requires a holistic and multi-sectoral approach – referred to as One Health. Resistant pathogens and antimicrobials can be found in humans, animals, plants, food and the environment, and they may spread from one to another, across national borders.

This call for research projects, developed under the ERA-Net JPIAMR-ACTION, is the 16th transnational call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The primary aim of the call is to combine the resources, infrastructures, and strengths of multiple countries in order to facilitate research projects supporting the development or improvement of existing strategies, tools, technologies, and methods to support the prudent and rational use of antimicrobials. This can be achieved by focusing on diagnosis of infections caused by resistant microorganisms, on detection of resistant microorganisms, and/or collection, analysis and use of antimicrobial resistance (AMR) and antimicrobial use (AMU) data.

2. Aim of the call

To take action against the growing global threat of increasing resistance in pathogenic organisms, and the spread of AMR, this call aims to fund research projects developing novel or improving existing strategies, tools, technologies and methods for (1) diagnosis and/or (2) One Health AMR surveillance.

Diagnostics should aid “prudent use” and stewardship of antimicrobials e.g. through supporting pathogen and/or resistance pattern identification within clinical and community settings, or the use of appropriate antimicrobials in agricultural and environmental settings.

Surveillance should guide the understanding of the risk and direction of AMR spread and assist the development of interventions to limit the spread of AMR within and between humans, animals, plants and the environment.

In the scope of this call, antimicrobials include antibiotics, antifungals and disinfectants (biocides).

It is expected that, through international collaborations combining complementary and synergistic research strengths, this JPIAMR call will result in the development of measures to limit the development and spread of AMR and address the urgent need to curb the burden associated with AMR. The results of the funded projects should contribute to improved understanding, monitoring, detection and mitigation of infection and AMR, or optimisation of AMU where efforts to curb AMR will have a global impact on human, animal and plant health and food safety and security.

---

2.1 Topics of the call

Projects should aim to address unmet needs in the AMR diagnostics and surveillance sectors beyond the current state of the art, by focusing on one of the topics of the call:

Topic 1:

to develop novel, or improve existing, diagnostics, including point of care diagnostics, that can rule out antimicrobial use or help identify the most effective antimicrobial treatment. Within this topic projects may:

- Develop new, improve or repurpose existing strategies, technologies, and methods for the rapid, accurate and affordable detection of bacterial or fungal infection and/or resistance patterns and elements.
- Study ways to facilitate and implement the uptake and use of existing diagnostics in varied economic settings.
- Optimise the use of tools, technologies, and methods for diagnostic data capture and usage, for example in conjunction with surveillance strategies.

OR

Topic 2:

to develop or improve existing strategies, technologies or methods, or data use strategies to support One Health AMR surveillance. Within this topic projects may:

- Develop new or improve existing strategies, technologies, and methods for the detection, analysis, monitoring and use of AMR and AMU data. This can include the analysis of existing data or the application of existing surveillance strategies, technologies, and methods to additional OH settings.
- Explore the standardisation, FAIRification and linkage of methodologies, datasets and relevant indicators to perform globally comparative, integrated and triangulated surveillance of AMR/AMU in humans, animals (including companion animals, livestock and wildlife), plants, food, and the environment.

Companies are welcome to apply to this call either by requesting funding or by using other internal or external funding. The eligibility of companies for funding from this call is determined by the relevant national funding partner organisation (FPO). Please check the National Rules and Requirements (Annex B) to see the eligibility for funding.

Applicants are encouraged to consider:

- future development of a diagnostic or surveillance tool following the conclusion of the project,
- the data that needs to be obtained at an early stage to support downstream diagnostic regulatory consideration and market authorisation (consider new EU IVDR as relevant),
- the inclusion of appropriate partners (commercial or non-commercial) in the project to support downstream development,
- appropriateness of the proposed platform technology for the specific need,
- test’s costs and cost savings and how these align with the intended use case,
- the current competitive landscape and how it aligns with the articulated need.

---

2 Please check national requirements to ensure your national agency has the possibility to fund social sciences and/or LMIC partners.
The following sub-topics are **out of the scope** of the call:

- antiviral and antiparasitic agents,
- proposals solely aiming to extend existing surveillance networks (e.g. GLASS, national surveillance programmes).

### 2.2 One Health settings

**The call covers the following One Health settings:**

- Human Health, and/or
- Animal Health (including wildlife, livestock, aquatic organisms, and companion animals), and/or
- Plants (including trees and crops), and/or
- Food, and/or
- Environment (including natural and built environment).

In the framework of this call, proposals addressing diagnostics (Topic 1) may focus within any individual One Health setting. Surveillance-focused proposals (Topic 2) should focus within two or more One Health settings. In case of proposals focusing on existing surveillance strategies, the proposal should extend to at least one additional OH setting.

**The eligibility of the considered One Health setting may depend on your funding organisation.** Please check the National Rules and Requirements (Annex B) to see if the One Health setting of interest is eligible for funding.

### 2.3 Type of studies/experimental approaches

In the framework of this call all types of studies or experimental approaches are admissible but **the eligibility of the proposed experimental approach may depend on your national funding organisation.** Please check the National Rules and Requirements (Annex B) to see if the type of study/experimental approach of your choice is eligible for funding.

Participation of end-users of the project outcomes, such as parties implementing antimicrobial stewardship activities, is encouraged.

### 3. Application

#### 3.1 Eligibility

Applicants must adhere to the specific regulations of their national funding partner organisations. The eligibility of the consortium will be approved by the Call Steering Group at both pre and full proposals stages. Therefore, each partner is strongly advised to check carefully the national eligibility rules defined by its own funding organisation, as specified in the National and Regional Requirements (see Annex B). A checklist for composing an eligible consortium is included on page 6 as Figure 1.

Eligibility rules for the consortia are:

- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
- The consortium can include a maximum of six (6) project partners (including non-funded partners, Figure 1). The maximum number of partners can be increased to seven (7) if the consortium includes:

---

Note: **UK is an EU country for the purpose of this call.**
- at least one partner from an under-represented country or
- at least one partner where the Principal Investigator meets the definition of an Early Career Researcher or
- a company.

- For the purposes of the DISTOMOS call:
  - the under-represented countries are Lithuania, Moldova, Poland, and Least Developed Countries,
  - Least Developed Countries (LDCs) are low-income countries confronting severe structural impediments to sustainable development, according to the DAC list of ODA recipients https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/DAC-List-of-ODA-Recipients-for-reporting-2022-23-flows.pdf. LDCs in sub-Saharan Africa can be funded by Sida. For details please consult Annex B;
  - the Principal Investigator is the applicant researcher scientifically responsible for the implementation of tasks by a national research team, and indicated as such in Section A of the proposal;
  - an Early Career Researcher (ECR) is a PhD holder, up to 8 years after the year of PhD award, holding a position at a recognized institution. The 8-year period may be extended to allow for career breaks including: parental leave, positions of trust in trade union organizations and student organizations, mandatory military or civil service, illness (own illness or care for close family members), medical internships or medical fellowship (applies to clinically active professionals). The last two categories may involve periods of up to 24 months each.

- Additional National Rules and Regulations (Annex B) of funding partner organisations also apply. LDCs should consult Sida Rules and Regulations.
- Project partners not eligible for funding (e.g. from countries not participating in the call or not fundable according to national/regional regulations of the funding partner organisations) may be involved in projects if they bring their own funding. The budget of non-funded partners must be included in the proposal and shall not exceed 30% of the requested total transnational project budget.
- The number of funded partners in the consortium must exceed the number of non-funded partners.
- A project partner not eligible to be funded cannot be the coordinator of a proposal but, like the funded partners, must accept all JPIAMR rules and guidelines.
- At both the pre- and full proposal stage, all partners, including non-funded partners, must submit a signed letter of intent along with their pre-/full proposal. In the absence of these letters, the proposal will be declared ineligible.
- Composition of the consortium should not be modified between the pre- and the full proposal except for the inclusion of a new partner as described in the paragraph 2.2 (widening), in case of force majeure/unforeseen event (e.g. change of professional affiliation, lab relocation, prolonged absence of the PI, etc.), or upon recommendation of the Peer Review Panel or request of the Call Steering Group. In any case, changes in the composition of the consortium must be approved by the Call Steering Group ahead of the submission of the full proposal.
3.2 Widening participation

In order to promote inclusiveness, ensure global participation, relevance and impact of the submitted projects in and outside Europe, as well as to maximise the use of committed resources, the Joint Call will employ the following widening measures:

- **at the pre-proposal stage** – increasing the maximum eligible size of consortia depending on their composition, as described in section 2.1;

- **at the full proposal stage** – increasing the initially declared size of consortium by adding one non-funded partner or one partner supported by the under-subscribed FPO (an FPO that is at risk of not using the total funds it committed to the call). Consortia which are invited to the

Figure 1. Consortium eligibility checklist
second stage of the call and which have not previously declared the maximum of seven (7) members will be able to increase their initial size by adding one new partner eligible for funding by an under-subscribed organisation from the list or one new partner not requesting funding. Consortium coordinators will be notified of this option in their invitation letter to submit a full proposal. The list of eligible under-subscribed organisations will be included in the full proposal template.

The Joint Call Secretariat and the under-subscribed FPOs will promote the use of the PST for widening, but coordinators will also be free to invite new partners who are not registered in the tool. In any case, new partners can only join consortia after their respective under-subscribed organisation confirms that they are indeed eligible according to the national regulations. The under-subscribed organisations will inform the Joint Call Secretariat of all new partners cleared to join at the full proposal stage.

3.3 Submission of joint transnational proposal

Submissions of proposals will take place in two steps; a pre-proposal and a full proposal phase. In both cases, one joint proposal document (in English, and using the provided template) shall be prepared by the project participants of a joint transnational proposal. The pre-proposal must be submitted by the coordinator before March 7, 2023, 14h CET using the electronic submission platform available on the JPIAMR website https://ptoutline.eu/app/jpiamr2023_distomos.

In addition, some funding partner organisations may require the submission of other documents at the national level - either at the first and/or second step. Details can be found in Annex B.

The two-step application process (pre-proposal, full proposal) will have the following targeted timetable:

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 18, 2022</td>
<td>Pre-announcement of the Call on European Antibiotic Awareness Day 2022</td>
</tr>
<tr>
<td>January 16, 2023</td>
<td>Publication of the Call</td>
</tr>
<tr>
<td>January 24, 2023</td>
<td>Interactive webinar presentation of the Call and partner search tool.</td>
</tr>
<tr>
<td>March 7, 2023</td>
<td>Submission deadline for pre-proposals</td>
</tr>
<tr>
<td>May 23, 2023</td>
<td>Full proposal invitations sent to project coordinators</td>
</tr>
<tr>
<td>July 4, 2023</td>
<td>Submission deadline for full proposals</td>
</tr>
<tr>
<td>September, 2023</td>
<td>Final funding decision taken by the funding partner organisations</td>
</tr>
<tr>
<td>October 2023</td>
<td>Ethical Evaluation of the selected proposals</td>
</tr>
<tr>
<td>November 2023</td>
<td>Final funding recommendation announced to applicants</td>
</tr>
<tr>
<td>Mid-November 2023</td>
<td>Publication of results: European Antibiotic Awareness Day 2023</td>
</tr>
<tr>
<td>End of 2023/early 2024</td>
<td>Start of funding</td>
</tr>
</tbody>
</table>
3.4 Financial modalities and funding prerequisites

Funding is initially granted for a maximum of three years in accordance with national regulations and applicable legal provisions. Applicants must comply with their own specific national regulations and scientific remits as detailed in the National and Regional Requirements or specific regulations of their corresponding funding partner organisation (see Annex B).

The financial indicative commitments made by the funding partner organisations are listed in the table below. Each country will fund its own approved project partners.

Initial funding committed by each Funding Partner Organisation

Please note the different currencies. The exchange rates for funders outside the Euro-zone are listed in the National Requirements (Annex B).

<table>
<thead>
<tr>
<th>Country</th>
<th>Funding Partner Organisation</th>
<th>Acronym</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>National Health and Medical Research Council</td>
<td>NHMRC</td>
<td>2 M AUD</td>
</tr>
<tr>
<td>Belgium</td>
<td>Fonds de la Recherche Scientifique</td>
<td>FNRS</td>
<td>200.000 EUR</td>
</tr>
<tr>
<td>Canada</td>
<td>Canadian Institutes of Health Research</td>
<td>CIHR</td>
<td>1,8 M CAD</td>
</tr>
<tr>
<td>Estonia</td>
<td>Estonian Research Council</td>
<td>ETAG</td>
<td>150.000 EUR</td>
</tr>
<tr>
<td>France</td>
<td>Agence Nationale de la Recherche</td>
<td>ANR</td>
<td>2 M EUR</td>
</tr>
<tr>
<td>Germany</td>
<td>Deutsches Zentrum für Luft- und Raumfahrt</td>
<td>DLR</td>
<td>3 M EUR</td>
</tr>
<tr>
<td>Ireland</td>
<td>Department of Agriculture, Food and the Marine</td>
<td>DAFM</td>
<td>250.000 EUR</td>
</tr>
<tr>
<td>Ireland</td>
<td>Health Research Board</td>
<td>HRB</td>
<td>370.000 EUR</td>
</tr>
<tr>
<td>Israel</td>
<td>Chief Scientist Office, Ministry of Health</td>
<td>CSO-MOH</td>
<td>320.000 EUR</td>
</tr>
<tr>
<td>Italy</td>
<td>Fondazione Regionale per la Ricerca Biomedica</td>
<td>FRRB</td>
<td>1,5 M EUR</td>
</tr>
<tr>
<td>Italy</td>
<td>Ministry of Health</td>
<td>It-MOH</td>
<td>800.000 EUR</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Research Council of Lithuania (Lietuvos mokslo taryba)</td>
<td>LMT</td>
<td>200.000 EUR</td>
</tr>
<tr>
<td>Moldova</td>
<td>Agentia Nationala Pentru Cercetare Si Dezvoltare</td>
<td>ANCD</td>
<td>50.000 EUR</td>
</tr>
<tr>
<td>Netherlands</td>
<td>The Netherlands Organisation for Health Research and Development</td>
<td>ZonMw</td>
<td>1 M EUR</td>
</tr>
<tr>
<td>Poland</td>
<td>National Science Centre</td>
<td>NCN</td>
<td>1 M EUR</td>
</tr>
<tr>
<td>South Africa</td>
<td>South African Medical Research Council</td>
<td>SAMRC</td>
<td>5 M ZAR</td>
</tr>
<tr>
<td>Country</td>
<td>Funding Partner Organisation</td>
<td>Acronym</td>
<td>Contribution</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------</td>
<td>----------------</td>
</tr>
<tr>
<td>Spain</td>
<td>Instituto de Salud Carlos III</td>
<td>ISCIII</td>
<td>500.000 EUR</td>
</tr>
<tr>
<td>Sweden</td>
<td>Swedish Research Council</td>
<td>SRC</td>
<td>15 M SEK</td>
</tr>
<tr>
<td>Sweden</td>
<td>Swedish International Development Cooperation Agency</td>
<td>Sida</td>
<td>2 M EUR</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Swiss National Science Foundation</td>
<td>SNSF</td>
<td>600.000 CHF</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Innovate UK</td>
<td>Innovate UK</td>
<td>1 M GBP</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Medical Research Council</td>
<td>UKRI MRC</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Biotechnology and Biological Sciences Research Council (with contributions from Veterinary Medicines Directorate)</td>
<td>UKRI BBSRC</td>
<td>2,23 M EUR</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Engineering and Physical Sciences Research Council</td>
<td>UKRI EPSRC</td>
<td></td>
</tr>
</tbody>
</table>

### 3.5 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat (JCS) (National Science Centre Poland, JPIAMR@ncn.gov.pl) and the project coordinator. Throughout the application procedure the Joint Call Secretariat will contact the project coordinators, who are obliged to forward all information to other partners of their consortia. Each funding partner organisation has national contact persons who can be contacted for information about the specific national requirements (see the contact list in Annex A).

Please note that country-specific requirements might apply to this call. Compliance with the national or institutional regulations specified in Annex B is mandatory. Applicants are strongly advised to contact their national funding partner organisation (see Annex A) prior to submitting a pre-proposal.

### 4. Evaluation

International experts will perform a remote written evaluation of the proposals. Following the remote evaluation, the international experts will meet, agree on a consensus evaluation of the proposals and recommend the pre-proposals that could be invited to submit a full proposal or the full proposals that could be recommended for funding depending on the evaluation stage.

Pre-proposals and full proposals will be assessed according to specific evaluation criteria listed below.

The adequacy of the proposals submitted to the call will be assessed by the evaluation panel. Proposals not relevant to the call topics and objectives will not be invited to submit a full proposal, regardless of their scientific quality.

A scoring system from zero (0) to five (5) will be used to evaluate the proposal’s performance with respect to the evaluation criteria given in section 4.2 below.
4.1 Scoring system

0: Failure. The proposal fails to address the criterion in question or cannot be judged because of missing or incomplete information.

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question.

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

3: Good. The proposal addresses the criterion in question well, but a number of improvements are possible.

4: Very good. The proposal addresses the criterion very well, but minor improvements are possible.

5: Excellent. The proposal successfully addresses all aspects of the criterion in question, there are no suggestions for improvement.

4.2 Proposal evaluation criteria

1. Excellence

<table>
<thead>
<tr>
<th>Criterion</th>
<th>For pre-proposal</th>
<th>For full proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Clarity and pertinence of the objectives.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>b. Credibility of the proposed approach and methodology, in relation to the research objectives.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>c. Soundness and research base of the concept.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>d. Novelty, ambition, timeliness, and innovation.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>e. Scientific excellence of the consortium</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

2. Impact

<table>
<thead>
<tr>
<th>Criterion</th>
<th>For pre-proposal</th>
<th>For full proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Impact of the proposal to improve diagnostics and/or surveillance. Justification of the choice of pathogen should be robust and demonstrate strength of need.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>b. Potential of the expected results for clinical, public health, and animal health, agriculture, or environmental benefit (including economic viability where appropriate).</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>c. Potential for fostering a longer term international network of researchers. For example, bringing together specific know-how and/or innovative technologies, gathering a critical mass of patients or biological material, sharing of resources (models, databases, biobanks, etc.), and international comparisons.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>d. Potential reach of the project results, including dissemination and communication measures. Accessibility of the proposed innovative strategy (different geographical areas, different populations.)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>e. Appropriateness of end user and stakeholder participation/engagement, for example, policy makers, industry, patient organisation, health and veterinary care, farmers, etc.</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
3. Quality and efficiency of the implementation

<table>
<thead>
<tr>
<th>Criterion</th>
<th>For pre-proposal</th>
<th>For full proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks within the given timeframe.</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>b. Adequate distribution of the tasks between the project partners considering the required expertise</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>c. Strength of the transnational collaboration (balanced geographical distribution of the tasks)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>d. Incorporation of social, economic, equity considerations and cultural sensitivity dimensions into the proposed research</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>e. Quality of the proposed Open Science practices, data management, Intellectual Property management, and Freedom to Operate where appropriate.</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>f. Appropriateness of the management and governance structures and procedures, including risk and innovation management.</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>g. Potential exploitation (including strategy to identify and address potential barriers) and relevance of the outcomes of the findings beyond the current project. (long term strategy)</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>h. Contingency plan, including risk assessment and mitigation (including of unforeseen circumstances like Covid-19).</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>i. Justification of the requested budget and cost-effectiveness of the project (appropriate distribution of resources in relation to project’s activities, partner responsibilities and time frame).</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Evaluation scores will be awarded for the three main criteria, and not singularly for the different aspects listed below the criteria, although these different aspects will be taken into account in scoring the main criteria. In order for an application to be considered fundable, the threshold score for individual criteria is set at three (3) (of a maximum of five (5)). The overall threshold for the score for all three criteria together is set at nine (9). The maximum score that can be reached from all three criteria together is 15 points.

4.3 Ethics and legal requirements

Proposals selected for funding will undergo an ethics review by an Ethics Panel. At the full proposal stage, in addition to the scientific content and if relevant, a full description of stakeholder engagement (or a justification if this is not applicable), safety, animal studies, genetically modified organisms and microorganisms, environmental hazards and waste handling, data management, statistical methods, ethics and legal issues will be required. Applicants should anticipate this requirement and ensure that they have consulted with relevant experts to verify the feasibility of the project, and that the proposal can be completed within the defined budget and within the prescribed time window. In the full proposal template a self-assessment checklist will need to be completed.

Each funded consortium must have all necessary ethics approvals for research on animals, and/or research involving human subjects or data/samples obtained from human subjects according to national/regional law and regulation and in compliance with EU Horizon 2020 rules before initiation of such research. Applications for ethics approval and ethics approvals should be made available immediately to the JPIAMR secretariat upon request. JPIAMR may perform an ethics review of the research at any time (evaluation and/or follow-up of the funded projects).
Project coordinators must inform the JPIAMR secretariat as well as the funders supporting the project if ethics approvals are denied. The notification should be communicated no more than 2 weeks after the rejection and the proposed rescue plan (new request for ethics approval, modification of the workplan/project scope) must be approved by the funders supporting the project.

Any partner of a consortium in breach of research ethics regulations will subject the whole project for re-evaluation by all funding organisations of the project resulting in potential inhibition of all activities, withdrawal of funds, cancelling of contracts, and/or legal action or other sanctions according to national law.

4.4 Social and gender equity, cultural sensitivity and economic viability

It is important that consortia and research proposals are founded upon principles of social and gender equity, cultural sensitivity and economic viability. Consortia are highly encouraged to apply these principles to the composition, leadership and management of research projects. Especially where LDCs are involved in the proposal, the impact to improving health and wellbeing should be considered.

Where relevant, research projects are expected to apply an intersectional and multi-dimensional approach by integrating sex, gender and other individual and population-level determinants of health (such as age, socio-economic status, ethnicity) into the project’s design, implementation, monitoring, evaluation and knowledge translation activities.

Research projects are expected to consider individual and population-level determinants of health when collecting and analysing data to design and/or implement interventions in ways that are accessible and affordable to target beneficiaries, to systematically capture and report on sex, gender, and other relevant factors in the project research outputs, and to meaningfully engage the participation of targeted marginalised groups in the research activities.

5. Decision of project to be funded

After peer review of the pre-proposals, selected consortia will be invited by email from the Joint Call Secretariat to submit a full proposal. The final funding decision will be taken by the Call Steering Group based on the review and the recommendation by the Peer Review Panel and will be subject to budgetary considerations and ethics review.

6. Reporting requirements and other obligations of JPIAMR grantees

Overall project monitoring will be the responsibility of the JPIAMR secretariat. On behalf of the project consortium, the coordinator is required to submit reports to JPIAMR according to the Monitoring policy for JPIAMR funded projects and networks. The following must be submitted:

- a mid-term report, on behalf of the consortium, 18 months after the project starts,
- a final report on research completed by the consortium, on behalf of the consortium, within 2 months of the end of the project,
- an ex-post report three years after the closure of the project.

The monitoring outcomes will be collected and made accessible to all funding organisations. In addition, the monitoring of each funded project may also be done through review seminars. The JPIAMR secretariat will contact the coordinator one month in advance of reporting deadlines and provide them with a link to the JPIAMR reporting system.

Outside of the above-listed reports, grantees have an obligation to supply the JPIAMR with updated information of the consortium and its results, if requested.
7. Intellectual Property

The ultimate goal of Joint Programming is to bring together national research efforts in order to make better use of public R&D resources and to tackle common global challenges more effectively in selected key areas.

For Joint Programming activities to contribute effectively to socioeconomic progress, the results of the research activities must be exploited. This requires appropriate identification and protection of the intellectual property being generated and effective knowledge transfer. Any particular protection and exploitation strategy should be agreed before the research activities start. The ten principles of Socially Responsible Licensing (SRL) should be part of this strategy.

Depending on the nature of the research and on the interests of the different parties, if there are opportunities for exploitation, it is recommended that parties decide in advance on either adopting a common exploitation strategy or leaving exploitation of results to the party best placed to commercialise it, with appropriate compensation mechanisms for the contributing parties. Please see section 7 for a link to a simplified consortium agreement template, available on the DESCA website. National rules and regulations may apply, please consult Annex B.

8. Partner Consortium Agreement

The consortium partners of each funded project are required to set up and sign a partner consortium agreement (PCA) in order to deal with any other issues related to the role, tasks and responsibilities within the consortium, the protection of intellectual property, and where applicable how the consortium will address the ten principles of SRL. The PCA needs to be in accordance with the national funding rules of the respective funding partner organisations - see Annex B. Upon request, this consortium agreement must be made available to the concerned funding organisations.

The CA must address (as a minimum), the following points:

- common start date and duration of the research project and the duration of the PCA;
- organisation and management of the project;
- role, tasks, and responsibilities of each partner;
- the resources and funding;
- confidentiality and publishing;
- Intellectual Property Rights (if applicable);
- how the ten principles of Socially Responsible Licensing will be addressed (if applicable);
- decision making within the consortium;
- handling of internal disputes;
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the PCA. The PCA together with any other information required by national/regional regulations must be made available on request to the national funding organisations and the JPIAMR secretariat.

Please see the DESCA website for further information on the development of a simplified consortium agreement under the Horizon 2020 Framework.

9. Open access and FAIR data

Following the ambitions of open access, researchers involved in JPIAMR funded projects must ensure that science and society can be made aware of the information about the project as early as possible in the research process.
In cases where there is information that cannot be shared (either by open access publication, or by sharing of data or biological materials), this must be explained, and substantiated in the JPIAMR reporting (e.g. temporary confidentiality may be accepted in the case of commercial exploitation).

Publications (open access):

Unless it goes against their legitimate interests, each beneficiary must — as soon as possible — disseminate its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium).

The JPIAMR promotes Green, Diamond and Gold Open Access measures, as recommended by the “Guidelines to the Rules on Open Access to Scientific Publications and Open Access to Research Data in Horizon 2020” (version 3.2 of March 21, 2017). Each participant may also be required to comply with the Open Access policy of its funding organisation (See country-specific information in Annex B).

In the context of the JPIAMR, the following policy applies:

- Publishing costs in an open access context, related to scientific results obtained in the context of a JPIAMR project, are considered eligible unless national funding regulations state to the contrary (see country-specific requirements in Annex B).
- Authors are encouraged to retain their copyright or, in case of transfer of copyright to third parties, at least to retain the right to disseminate via open access. National funding regulations may apply (see country-specific requirements in Annex B).

Research data (FAIR):

JPIAMR requires grant holders to make their data as much Findable, Accessible, Interoperable, and Reusable (FAIR) as possible. FAIR data may also be open data, however, restricted access to FAIR data is also possible. FAIR data allow researchers to verify research results and reuse data in future research. FAIR research data can typically be accessed, mined, exploited, reproduced and disseminated: under certain conditions, or free of charge for the user (=open).

Also biological materials (biospecimens, microbial strains/samples, molecular derivatives) need to be FAIR. This may be done by describing the biomaterials with metadata (and these are digital).

In the context of the JPIAMR, the following policy applies:

- JPIAMR expects researchers to create reusable research data and biological materials, and to maximize the opportunities to make the research data generated from their scientific work available.
- In case that data originates from ongoing projects, the funding conditions related to those projects needs to be taken into account. These conditions cannot be overruled by conditions for new projects.
- At the end of the project, the consortium needs to provide information on how the data and/or biological materials can be found (e.g. catalogue), where they are stored (repository), the conditions for access or use to the resources (e.g. open or restricted access).

What needs to be done in the application phase?

- Check the requirements for data management and data sharing of the relevant national funder.
- Plan the collection of research data, and biomaterials. Start planning a DMP (data management plan); consult a data expert; look for services from research infrastructures.
- Search for reusable data and biomaterials; ask for permission to use these.
- Take costs for data management and infrastructure into account when planning the budget.

For further information please consult:
- JPIAMR website

Call Text 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR ACTION
– the Science Europe “Practical Guide to the International Alignment of Research Data Management” with (1) core requirements for data management, allowing funders and research institutes to align their RDM requirements and template; (2) criteria for the selection of trustworthy repositories for storing and sharing research data https://www.scienceeurope.org/our-resources/practical-guide-to-the-international-alignment-of-research-data-management/


– the BBMRI services for ethical, legal and societal issues (ELSI) https://www.bbmri-eric.eu/services-support/

10. General Data Protection Regulation (GDPR)

Personal information provided by an applicant will be processed in accordance with article 6.1 (c) or 6.1 (e) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

– processing and evaluating the pre- and full proposal where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
– administering any subsequent funding award;
– managing the relationship between the applicant and the Funding Partner Organisations;
– analysing and evaluating the call;
– providing aggregate data to national and European surveys and analyses on the funded projects;
– complying with audits that may be initiated by the Funding Partner Organisations and the European Commission (or its agencies).

In addition, by submitting an application (pre- and full proposal) to the AMR diagnostics and surveillance 2023 Call, the applicants agree to share their personal data with Funding Partner Organizations based outside the European Economic Area (see table on p. 16) and with third parties such as evaluators (some of which may be based outside the European Economic Area) in relation to the above activities.

The following FPOs outside the European Economic Area will use their national data protection rules:

• Australia (NHMRC)
• Canada (CIHR)
• Israel (CSO-MOH)
• Moldova (ANCD)
• South Africa (SAMRC)
• Switzerland (SNSF)
• the United Kingdom (UKRI)

By the time of the call launch, the European Commission issued adequacy decisions for personal data protection laws in Israel, Switzerland and the United Kingdom.

Funding Partner Organizations and third parties may link the data that applicants provide in the application with national, bibliographic or external research funding data which is available through public subscription based databases (e.g. Scopus, Web of Science, etc.) or other national/open datasets.
11. Privacy

Responding to a JPIAMR call for proposals, both as coordinator or partner, gives JPIAMR and Funding Partner Organisations the right to use and store the information submitted for analysis of the call success rate, national response rate, etc. Information will only be shared between the Funding Partner Organisations and the JPIAMR secretariat, except for consortia including partners applying for funding from a Swedish FPO (SRC or Sida). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines.

Accepting a JPIAMR grant award and associated grant contract from a national funding organisation gives JPIAMR and Funding Partner Organisations the right to store, share, and analyse information on beneficiaries and consortia (rules may differ between different countries). Composition of the awarded consortia (Principal investigators, Institution) as well as the title, acronym and abstract of funded projects will be published and openly accessible. No data will be shared with third parties or commercial entities without the formal consent of the project coordinators, except for consortia including partners applying for funding from a Swedish Funder (SRC or Sida). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines.

12. Acknowledgements

All results disseminated by the funded projects (in any form, including electronic) should acknowledge funding from the JPIAMR and include the following text: This project (project acronym/name) has been supported by (name of the national funder) under the framework of the JPIAMR - Joint Programming Initiative on Antimicrobial Resistance.
Annex A: National contact persons for each party providing funding

**JPIAMR DISTOMOS JOINT CALL SECRETARIAT (JCS)**
National Science Centre, Poland (NCN)

Contact persons:
Jolanta Palowska; Monika Pobiega
e-mail: JPI.AMR@ncn.gov.pl
Tel. +48 695 211 478

<table>
<thead>
<tr>
<th>Country</th>
<th>Funding org.</th>
<th>Contact person(s)</th>
<th>Email</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>NHMRC</td>
<td>Adam Chapman, Kirilly Agnew, Lina Gubhaju</td>
<td><a href="mailto:international@nhmrc.gov.au">international@nhmrc.gov.au</a></td>
<td>+1 613.954.1968, +1-888-603-4178</td>
</tr>
<tr>
<td>Belgium</td>
<td>FRS FNRS</td>
<td>Agnès Roba, Florence Quist</td>
<td><a href="mailto:international@frs-fnrs.be">international@frs-fnrs.be</a></td>
<td>+32 (0)2 504 92 36, +32 (0)2 504 93 51</td>
</tr>
<tr>
<td>Canada</td>
<td>CIHR</td>
<td>Contact Centre</td>
<td><a href="mailto:support-soutien@cihr-irsc.gc.ca">support-soutien@cihr-irsc.gc.ca</a></td>
<td>+33 1 78 09 80 39, +33 1 73 54 81 74, +33 1 78 09 80 22</td>
</tr>
<tr>
<td>Estonia</td>
<td>ETAG</td>
<td>Argo Soon, Margit Suuroja</td>
<td><a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a>, <a href="mailto:margit.suuroja@etag.ee">margit.suuroja@etag.ee</a></td>
<td>+372 730 0372, +372 731 7360</td>
</tr>
<tr>
<td>France</td>
<td>ANR</td>
<td>Sophie Gay, Séverine Olivier, Ingrid Pfeifer</td>
<td><a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a></td>
<td>+372 730 0372, +372 731 7360</td>
</tr>
<tr>
<td>Germany</td>
<td>DLR</td>
<td>Barbara Junker, Akin Akkoyun</td>
<td><a href="mailto:Barbara.junker@dlr.de">Barbara.junker@dlr.de</a>, <a href="mailto:Akin.akkoyun@dlr.de">Akin.akkoyun@dlr.de</a></td>
<td>+49 228 3821 1274, +49 228 3821 1864</td>
</tr>
<tr>
<td>Ireland</td>
<td>DAFM</td>
<td>Pat Kelly</td>
<td><a href="mailto:Pat.Kelly@agriculture.gov.ie">Pat.Kelly@agriculture.gov.ie</a></td>
<td>+353 87 16 12 12, +353 87 16 12 12</td>
</tr>
<tr>
<td>Ireland</td>
<td>HRB</td>
<td>Amanda Daly, Siobhan Hackett</td>
<td><a href="mailto:Amanda.Daly@hrb.ie">Amanda.Daly@hrb.ie</a>, <a href="mailto:eujointprogrammes@hrb.ie">eujointprogrammes@hrb.ie</a></td>
<td>+353 87 16 12 12, +353 87 16 12 12</td>
</tr>
<tr>
<td>Israel</td>
<td>CSO-MOH</td>
<td>Ronit Meyuhas, Irit Allon</td>
<td><a href="mailto:Ronit.meyuhas@moh.gov.il">Ronit.meyuhas@moh.gov.il</a>, <a href="mailto:Irit.allon@moh.gov.il">Irit.allon@moh.gov.il</a></td>
<td>+97225082159, +97225082167</td>
</tr>
<tr>
<td>Italy</td>
<td>FRRB</td>
<td>Paola Bello, Carmen De Francesco, Giusi Caldieri</td>
<td><a href="mailto:progetti@frrb.it">progetti@frrb.it</a></td>
<td>+ 39 02 67650174</td>
</tr>
<tr>
<td>Italy</td>
<td>IT-MOH</td>
<td>Maria Jose Ruiz Alvarez, Chiara Ciccarelli</td>
<td><a href="mailto:mj.ruizalvarez-esterno@sanita.it">mj.ruizalvarez-esterno@sanita.it</a>, <a href="mailto:c.ciccarelli@sanita.it">c.ciccarelli@sanita.it</a></td>
<td>+39 06 5994 3214 / 06 49906836, +39 06 59943919</td>
</tr>
<tr>
<td>Lithuania</td>
<td>RCL</td>
<td>Živilė Ruželė</td>
<td><a href="mailto:Zivile.ruzele@lmt.lt">Zivile.ruzele@lmt.lt</a></td>
<td>+37067614383</td>
</tr>
<tr>
<td>Moldova</td>
<td>ANCD</td>
<td>V. Boaghi, S. Postoronca</td>
<td><a href="mailto:Viorica.boaghi@ancd.gov.md">Viorica.boaghi@ancd.gov.md</a>, <a href="mailto:Sveatoslav.postoronca@ancd.gov.md">Sveatoslav.postoronca@ancd.gov.md</a></td>
<td>+373 22 272339, +373 22 294865</td>
</tr>
<tr>
<td>Country</td>
<td>Funding org.</td>
<td>Contact person(s)</td>
<td>Email</td>
<td>Telephone</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>-----------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Netherlands</td>
<td>ZonMw</td>
<td>Linda van Gaalen, Nora Wolff, Anouk Warmerdam</td>
<td><a href="mailto:jpiamr@zonmw.nl">jpiamr@zonmw.nl</a></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>NCN</td>
<td>Monika Pobiega, Jolanta Palowska</td>
<td><a href="mailto:JPI.AMR@ncn.gov.pl">JPI.AMR@ncn.gov.pl</a></td>
<td>+48 123 419 176, +48 695 211 478</td>
</tr>
<tr>
<td>South Africa</td>
<td>SAMRC</td>
<td>Zoleka Ngcete</td>
<td><a href="mailto:Zoleka.Ngcete@mrc.ac.za">Zoleka.Ngcete@mrc.ac.za</a></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>ISCIII</td>
<td>Cándida Sanchez Barco</td>
<td><a href="mailto:cbarco@isci.es">cbarco@isci.es</a></td>
<td>+34 918222063</td>
</tr>
<tr>
<td>Sweden</td>
<td>SIDA</td>
<td>Markus Moll</td>
<td><a href="mailto:Markus.Moll@sida.se">Markus.Moll@sida.se</a></td>
<td>+46721434246</td>
</tr>
<tr>
<td>Sweden</td>
<td>SRC</td>
<td>Kristian Haller</td>
<td><a href="mailto:Kristian.haller@vr.se">Kristian.haller@vr.se</a></td>
<td>+46 8 546 12 307</td>
</tr>
<tr>
<td>Switzerland</td>
<td>SNSF</td>
<td>Georges Klein</td>
<td><a href="mailto:amr@snf.ch">amr@snf.ch</a></td>
<td>+41 31 308 22 22</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Innovate UK</td>
<td>Lewis Oakley</td>
<td><a href="mailto:Lewis.oakley@iuk.ukri.org">Lewis.oakley@iuk.ukri.org</a>, <a href="mailto:jo.frost@iuk.ukri.org">jo.frost@iuk.ukri.org</a></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>UKRI MRC</td>
<td>Danielle Sagar</td>
<td><a href="mailto:Danielle.Sagar@mrc.ukri.org">Danielle.Sagar@mrc.ukri.org</a></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>UKRI BBSRC</td>
<td>Stephen Webb</td>
<td><a href="mailto:Stephen.webb@bbsrc.ukri.org">Stephen.webb@bbsrc.ukri.org</a></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>UKRI EPSRC</td>
<td>Andrew Eustace</td>
<td><a href="mailto:Andrew.Eustace@epsrc.ukri.org">Andrew.Eustace@epsrc.ukri.org</a></td>
<td></td>
</tr>
</tbody>
</table>
**Annex B: National Rules and Requirements**

**Important note to applicants:** Applications to JPIAMR joint transnational calls can require the submission of additional information on national funding platforms. All applicants must have fulfilled both joint and national requirements for an application to be eligible.

This is only a summary. Refer to national websites and contact the respective contact person for full details.

<table>
<thead>
<tr>
<th>Australia – NHMRC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Health and Medical Research Council</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Specific National/Regional rules</strong></td>
<td>Institutions must be a NHMRC Administering Institution to be eligible to receive and administer NHMRC funding. Applications for NHMRC funding are subject to the general eligibility requirements as set out in the <em>JPIAMR: Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance</em> grant guidelines when available and within the NHMRC Funding Agreement. Applicants should read all relevant reference material. Applicants from Australia intending to apply for funding via NHMRC should notify the national contact point by email to signal an intention to join a consortium, via <a href="mailto:international@nhmrc.gov.au">international@nhmrc.gov.au</a>.</td>
</tr>
<tr>
<td><strong>Eligible costs</strong></td>
<td>Refer to NHMRC Direct Research Costs guidelines: <a href="http://www.nhmrc.gov.au/funding/manage-your-funding/funding-agreement">www.nhmrc.gov.au/funding/manage-your-funding/funding-agreement</a></td>
</tr>
<tr>
<td></td>
<td>There is no minimum value for grants funded through this grant opportunity. The amount of funding for each JPIAMR grant will be based on assessment of the requested budget. Applications must clearly justify the requested duration and budget and how they will support the proposed outcomes of the research. Internal NHMRC budget review will consider this information and NHMRC may alter the duration and/or budget to ensure the research aims and objectives can be achieved while ensuring value with money. An altered budget does not alter the scope of the proposed research activity.</td>
</tr>
<tr>
<td><strong>Additional documents required</strong></td>
<td>Full proposals to be submitted through the NHMRC grant management system (Sapphire)</td>
</tr>
<tr>
<td><strong>Eligible One Health settings</strong></td>
<td>Projects addressing human health and environment (where relevant to human health) will be eligible for funding. NHMRC will not fund projects that do not include human health research activities.</td>
</tr>
<tr>
<td><strong>Eligible experimental approaches</strong></td>
<td>Projects involving <em>in silico</em>, <em>in vitro</em>, <em>in vivo</em> and pre-clinical and/or clinical trials are eligible under this Funding Opportunity.</td>
</tr>
<tr>
<td><strong>Further information</strong></td>
<td>The total provisional funding allocation for this funding call is $2 million AUD. The NHMRC funding allocation will be distributed to successful grants until the $2 million funding allocation is exhausted. NHMRC’s Research Committee reviews and recommends indicative budget amounts to be awarded across individual funding schemes annually. Australian applicants should refer to the <a href="http://www.nhmrc.gov.au">NHMRC website</a> and <a href="http://www.grantconnect.com.au">GrantConnect</a> for specific information on this Grant Opportunity when it becomes available. NHMRC funding is subject to governmental approval processes.</td>
</tr>
</tbody>
</table>
Belgium – FNRS

Fonds de la Recherche Scientifique

Specific National/Regional rules

All eligibility rules and criteria can be found in the PINT-Multi regulations.

Eligible costs

All eligibility rules and criteria can be found in the PINT-Multi regulations.

“Overhead” is not an eligible cost. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.

Additional documents required

Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on e-space within 5 working days after the general deadline of JPIAMR action to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.

Eligible One Health settings

All 3 research areas (Human Health, Animal Health and Environment) are eligible for funding.

Eligible experimental approaches

Clinical studies are not eligible for funding by the F.R.S.-FNRS.

Further information

Additional national eligibility criteria for the proposal beyond the general criteria of the joint call:
- Basic research (low Technology Readiness Level) carried out in a research institution from the “Fédération Wallonie-Bruxelles”
- The F.R.S.-FNRS will not fund clinical research
- The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector

Canada – CIHR

Canadian Institutes of Health Research

Specific National/Regional rules

Among eligible organisations that CIHR may fund are non-governmental organisations with a research or knowledge translation mandate. Details regarding eligible applicants for a given competition will be specified in the funding opportunity on ResearchNet.

Individuals in the Nominated Principal Applicant role must be affiliated with a CIHR eligible Canadian postsecondary institution and/or their affiliated institutions; individuals working with municipal, provincial, and/or territorial governments are also eligible where the research proposed is not already funded by that Government of Canada sector.

Individuals in the Nominated Principal Applicant role must have their substantive role in Canada for the duration of the requested grant term. Note that CIHR is not prescriptive regarding the duration of time that a NPA must physically reside in Canada, as this falls under the purview of applicable policies of the administering institution, employment terms and conditions, and or collective agreements.

Appointments and/or positions that can be renewed prior to the end of the requested grant term are eligible at the discretion of the administering institution.
**Canada – CIHR**

**Canadian Institutes of Health Research**

CIHR grants and awards are paid to CIHR-eligible institutions, through a CIHR account, from which the Nominated Principal Applicant draws funds.

Canadian applicants must complete a CIHR application and submit it using ResearchNet in addition to the proposal submitted to the Joint Call Secretariat.

Canadian applicants must submit an Operating Budget for the project, with the amounts quoted in Canadian dollars, and a complete justification for funds requested using ResearchNet in addition to the proposal submitted to the Joint Call Secretariat. The deadline for submission of this application is the same as the proposal deadline to the Joint Call Secretariat.

Projects receiving a CIHR grant must comply fully with the CIHR Funding Policies. Policies and guidelines cover areas such as Applicant Responsibilities, Official Languages policy, Access to Information and Privacy Acts. For more information, please refer to Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) and Tri-Agency Framework: Responsible Conduct of Research.

To complete the ResearchNet application for funding you must include your personal information. CIHR will collect, use, retain and dispose of your personal information in accordance with the Access to Information and Privacy Act. If applicable, the information provided may be shared, in whole or in part, with CIHR Institute Staff. CIHR will not share the information collected through your abbreviated application in CIHR ResearchNet with other institutions or signatories to the JPIAMR.

Funding applications submitted to JPIAMR will be held in jurisdictions outside of Canada and will not be subject to the provisions of the Privacy Act. Information submitted to JPIAMR as part of the applications will be governed by the provisions of EU data protection laws, the European Data Protection Regulation (GDPR). Please note that all parties on applications must also comply with (GDPR) (2016/679).

Canadian applicants do NOT need to submit the pre-proposal through CIHR ResearchNet. ONLY the full proposal.

**Eligible costs**

Applicants should review the Use of Grant Funds Section of the Tri-Agency (CIHR, NSERC and SSHRC) Guide on Financial Administration for a complete listing and description of allowable costs and activities.

**Additional documents required**

Applications submitted to CIHR require applicant consent and institutional approval (if applicable) to the use and disclosure of full application and nominative information for relevance review and funding decisions at the time of application.

- The applicant will be required to submit to all JPIAMR reporting requirements.
- The Nominated Principal Applicant will be required to submit an Electronic Final Report to CIHR. This online report will be made available to the Nominated Principal Applicant on ResearchNet at the beginning of the grant funding period and can be filled in as the research progresses.
- All reports may be shared with partners supporting the grant.
- The Nominated Principal Applicant must have successfully completed one of the sex- and gender-based analysis training modules available.
| **Canada – CIHR**  
<table>
<thead>
<tr>
<th><strong>Canadian Institutes of Health Research</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>online through the CIHR Institute of Gender and Health and have submitted a Certificate of Completion (see How to Apply section). Select and complete the training module most applicable to your research project. Applicants are encouraged to review the &quot;How to integrate sex and gender in research&quot; section on the CIHR website. CIHR is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in research, training and knowledge translation. CIHR’s position on equity, diversity and inclusion (EDI) is available in the Tri Agency Statement on Equity, Diversity and Inclusion. Additional guidance can be found on the Best practices in Equity, Diversity and Inclusion in Research webpage. It is noted that CIHR does not retain or claim any rights to IP in relation to research that if funds. Accordingly, the Canadian researchers retain full freedom in negotiating the Partner Consortium Agreement (PCA) required, including whether or not to accept the IP conditions. The Nominated Principal Applicants do NOT need to send a signed copy of the PCA to CIHR.</td>
</tr>
</tbody>
</table>

| **Eligible One Health settings** | Projects addressing human health will be eligible for funding. CIHR will NOT be funding projects on animal health, plants, food, and/or environment that do not include human health research activities. |

| **Eligible experimental approaches** | Projects involving pre-clinical and/or clinical trials are eligible under this Funding Opportunity. |

| **Further information** | The total amount available for the Canadian component is $1,8M CAD, enough to fund the Canadian component of up to 3 joint transnational teams: The Canadian Consortium Coordinator can receive up to CAD $200,000 per year for three (3) years for a maximum of CAD $600,000 for the Canadian component of the joint transnational team. The Canadian Consortium Partner can receive up to CAD $166,667 per year for three (3) years for a maximum of CAD $500,000 for the Canadian component of the joint transnational team. The proposals will be funded based on the ranking list recommended by the Peer Review Panel and decided by the Call Steering Group. The final funding decision will be made by the national/regional funding organisations and will be subject to budgetary considerations with the goal of optimal usage of the available budget. Approved joint transnational teams may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities. For full details of CIHR’s requirements, please refer to the Funding Opportunity on ResearchNet. |

---

Call Text 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR ACTION
### Eligible costs

Research expenses consist of direct costs (personnel costs, travel costs and other direct costs) and subcontracting costs. The research expenses must be used to carry out the project and be separately identifiable.

#### Direct costs

1. **Personnel costs** are monthly salaries with social security charges and all the other statutory costs of the project participants, calculated according to their commitment and in proportion to their total workload at their Host Institution.
2. **Travel costs** may cover expenses for transport, accommodation, daily allowances and travel insurance.
3. **Other direct costs** are:
   - consumables and minor equipment related to the project;
   - publication and dissemination of project results;
   - organising meetings, seminars or conferences (room rent, catering);
   - fees for participating in scientific forums, conferences and other events related to the project;
   - patent costs;
   - all other costs that are identifiable as clearly required for carrying out the project (e.g. translation, copy editing, webpage hosting, etc.) and comply with the eligible costs.

4. **Subcontracting costs** should cover only the additional or complementary research related tasks (e.g. analyses, conducting surveys, building a prototype, etc.) performed by third parties. Subcontracting costs should not be included in the overhead calculation. The activities and budget should be described in the proposal. Core project tasks should not be subcontracted. Subcontracting costs may not exceed 15% of the total costs.

Indirect costs are overhead from the personnel costs only, which may not exceed 15% and should cover the general expenses of the Host Institution. Costs for equipment and services intended for public use (a copy machine or a printer that is publicly used, phone bills, copy service, etc.) should be covered from the overhead.

Double funding of activities is not acceptable.

### Additional documents required

The beneficiary must confirm to Estonian Research Council (with a confirmation letter after the submission deadline) that the project can be carried out on their premises and that they will employ the Principal Investigator during the proposed project, should the project receive funding.

### Eligible One Health settings

Projects addressing both human and animal health will be eligible for funding.

### Eligible experimental approaches

Projects involving pre-clinical and/or clinical trials are eligible under this Funding Opportunity.

### Further information

ETAG will fund one project in amount of € 150 000. Eligibility criteria in detail: [https://etag.ee/wp-content/uploads/2022/07/Vastavusnouded-RV-uhiskonkurssidel_30.08.22.pdf](https://etag.ee/wp-content/uploads/2022/07/Vastavusnouded-RV-uhiskonkurssidel_30.08.22.pdf)
| Specific National/ Regional rules | ANR may fund research organisations and undertakings, as defined by the EC regulation on State aid for research, development and innovation (see the ANR Funding regulations for further reference).

As for research organisations, only those that have their primary establishment in France may be funded. As for undertakings, those that have their real head office in an EU member State and having an establishment (primary or secondary) in France may be funded.

Within this framework, research institutions such as EPST, EPIC, Universities, Hospitals, most foundations, as well as companies and NGOs (associations) can apply. This list is not comprehensive and funding rates vary. Please fill the form related to economical activities to identify your funding rate and consult the “règlement financier” http://www.agence-nationale-recherche.fr/RF for more details.

Please note that companies with economic difficulties cannot receive ANR subventions.

Countries subject to sanction(s) by the European Union authorities are excluded from this call. At the time of publication, these countries include the following: Belarus, Russia. Projects including partners from these countries will be declared ineligible by ANR. The list might evolve and application measures be taken accordingly.

| Eligible costs | Standard ANR funding rules apply for eligible costs. These rules are specified in ANR’s “Règlement financier” mentioned above and in an explanatory note available at: https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf

Eligible costs (e.g.: personnel costs of non-permanent researchers, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partners. Please note that expenses related to permanent staff are not eligible for the beneficiaries “à coût marginal”. For the beneficiaries “à coût marginal”, please note that overheads correspond to 13.5% of the eligible costs (10.5% dedicated to “tutelle gestionnaire” and 3% to the laboratory).

Please note that double funding of research projects is not permitted. ANR will perform cross-checks of submissions against other joint transnational (JPIAMR, ICRAD,...) and national calls (including AAPG and the PPR “antibiorésistance”). Partners may not apply for funding for the same research activities in different calls. In addition, there can be no double funding for activities already funded by EC H2020 and Horizon Europe calls. In case of any doubts, please contact your national contact point before submission.

| Additional documents required | No additional documents should be submitted to ANR during the submission phase. If a project is selected for funding, French partners will have to fill administrative and financial data on the ANR platform.

| Eligible One Health settings | All 5 research areas (Human Health, Animal Health, Plants, Food and the environnement) are eligible for funding. |
### France – ANR  
French National Research Agency

<table>
<thead>
<tr>
<th>Eligible experimental approaches</th>
<th>All approaches with the exception of phase III clinical trials.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Early Stage Researchers</td>
<td>To be eligible for this call as Principal Investigator, early stage researchers must hold a research position in an eligible institution covering the duration of the project. The salary of the Early Stage researcher will not be covered by the present grant. Early stage researchers who will apply to this call as Principal Investigator must imperatively send the documents proving their eligibility by mail to the ANR contact point (<a href="mailto:jpi-amrcalls@agencerecherche.fr">jpi-amrcalls@agencerecherche.fr</a>) before the closing of the call. Early stage researchers do not need to head their own lab, or group while applying. If an early stage researcher does not head its own research group/lab, the signature of the head of the department should be included in the letter of intent, even at the pre-proposal stage.</td>
</tr>
</tbody>
</table>

### Further information

<table>
<thead>
<tr>
<th>Maximum amount per project:</th>
<th>460 000 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum funding per partner:</td>
<td>260 000 € (Increased to 310 000 € for coordinators)</td>
</tr>
<tr>
<td>Minimum amount per partner:</td>
<td>15 000 €</td>
</tr>
</tbody>
</table>


### Germany – DLR  
Deutsches Zentrum fuer Luft – und Raumfahrt Ev

<table>
<thead>
<tr>
<th>Specific National/Regional rules</th>
<th>Legal bodies:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Universities</td>
</tr>
<tr>
<td></td>
<td>• University hospitals</td>
</tr>
<tr>
<td></td>
<td>• Non-university research institutes</td>
</tr>
<tr>
<td></td>
<td>• Industry</td>
</tr>
<tr>
<td>Note: industry is funded with a maximum of 50-60% of their costs.</td>
<td></td>
</tr>
</tbody>
</table>

| Eligible costs | Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Overheads refer to “Gemeinkosten” (applicable e.g. for Helmholtzcentres and Fraunhofer-Society) as well as “Projektpauschale” (applicable for universities and university hospitals). Individual project coordinators/partners may request up to 300 000 Euro including overheads. A project consisting of two or more German partners may request a maximum of 500 000 Euro including overheads. For further details please refer to the national guidelines “BMBF Formularschrank” |

<table>
<thead>
<tr>
<th>Additional documents required</th>
<th>no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible One Health settings</td>
<td>all</td>
</tr>
<tr>
<td>Eligible experimental approaches</td>
<td>all</td>
</tr>
</tbody>
</table>
| Germany – DLR  
Deutsches Zentrum fuer Luft – und Raumfahrt Ev  
Further information | For further details please refer to the national guidelines “BMBF Formularschrank”  
https://foerderportal.bund.de/easy/easy_index.php?auswahl=formularschrank_forerportal&formularschrank=bmbf |
| Ireland – DAFM  
Department of Agriculture, Food and the Marine  
Specific National/Regional rules | National eligibility criteria:  
1. Grant applications will only be accepted from DAFM approved Irish RPOs  
2. The grant request by Irish RPOs must not exceed the maximum funding per project as set out in the relevant Guidelines for Irish Applicants  
3. Address at least one of the JPIAMR-ACTION’s Call’s scientific topic areas (as set out in the central JPIAMR-ACTION Call announcement)  
4. Avoid duplication of recent research work already undertaken or ongoing that incorporates the scope of the scientific topic areas in the JPIAMR-ACTION Call  
5. Closely align with applicable Strategic Research and Innovation Agenda priority areas  
6. Align with relevant national policy and foresight documents.  
Applications that do not adhere to these criteria will be deemed ineligible and in such cases the application will not proceed for expert review. |
| Eligible costs | Eligible costs will be allowed in the categories of:  
(a) Staff Costs  
(b) Equipment  
(c) Travel and Subsistence (T&S)  
(d) Consumables  
(e) Overheads  
(f) Other agreed costs e.g. Sub-Contracting |
| Additional documents required | Guidelines for Applicants’ located on the DAFM website which sets out in more detail the rules for Irish applicants seeking grant-aid and which must be read in conjunction with the requirements set out in the National Annex. |
| Eligible One Health settings | Animal health, environmental health. |
| Eligible experimental approaches | Standard National Grant Conditions apply. |
| Further information |  

Call Text 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR ACTION
## Ireland – HRB
### Health Research Board

| Specific National/Regional rules | Applicants based in Ireland and seeking HRB funding must consult the HRB Guidance and FAQs for this call, for important eligibility information: [HRB Funding Schemes](#). Lead applicants (Principal Investigators) must be from a recognised HRB Host Institution ([Policy on Approval of HRB Host Institutions](#)) and meet specific criteria. Early Career Researchers must have:
|  | • A PhD or have been granted PhD equivalence by the HRB before submission.  
|  | • At least four years and up to seven years active post PhD (or equivalent) research experience. |

| Eligible costs | Funding available is inclusive of overheads (in line with [HRB's Policy on usage of overheads](#)) and pension contributions and will cover research related costs including:
|  | • salary for research staff  
|  | • running costs (including travel and Public, Patient and Carer involvement costs)  
|  | • FAIR data management costs  
|  | • equipment (up to €10,000)  
|  | • dissemination costs (including dissemination-related travel).  
|  | For consortium coordinators, the additional €130,000 for coordination-specific activities will not cover equipment or consumables. |

| Additional documents required | Irish partners will be asked to provide a list of their deliverables and supplementary budget information at full proposal stage. Templates will be provided by the HRB following invitation to submit a full proposal. A letter of support will be required at submission stage for any Lead Applicants who do not have a permanent post. Please refer to the guidance on the [HRB scheme page](#) for further information.  
|  | For successful projects, the HRB Host Institution will be required to submit annual financial and scientific reports. |

| Eligible One Health settings | HRB can only fund activities addressing Human Health. At least one of the settings must be in Human Health and the Irish partner’s activities must primarily target this area. |

| Eligible experimental approaches | Irish Partner(s) are not eligible for HRB funding for:
|  | • Proposals seeking to evaluate a pilot or feasibility study.  
|  | • Proposals seeking to evaluate a definitive intervention.  
|  | • Proposals involving basic biomedical research.  
|  | Research intended to create human embryos solely for the purposes of research or for the purposes of stem cell procurement, including by means of somatic cell nuclear transfer. |

| Further information | Please refer to HRB’s guidance on the [HRB scheme page](#) or contact Siobhán Hackett at eujointprogrammes@hrb.ie for full information. |
### Israel – CSO-MOH
Chief Scientist Office, Ministry of Health

| Specific National/Regional rules | CSO-MOH (Israel) will only fund proposals with relation to Human Health. PI should hold a Ph.D., M.D., D.M.D., D.Sc or equivalent degree and employed by an eligible institution (hospitals, clinics, laboratories, academic and public research institutions). Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme. |
| Eligible costs | Materials and consumables; Travel (up to 10%); No salaries for PIs; No heavy equipment, Institutional overhead 10%. Available budget: 0.32M (up to 2 projects. 140K per project + additional 20K per project coordinators) |
| Additional documents required | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later. |
| Eligible One Health settings | Human health, Animal health, Environmental health (Only in relation to human health). |
| Eligible experimental approaches | Standard National Grant Conditions apply |
| Further information | Please see detailed instructions of application at the national level and reporting at [https://www.gov.il/he/service/era-net-instructions-for-israeli-researchers](https://www.gov.il/he/service/era-net-instructions-for-israeli-researchers) |

### Italy – It-MoH
Italian Ministry of Health

| Specific National/Regional rules | Initial funding pre-commitment 800 M€
Anticipated number of potential project partners: 2
Maximum funding per grant awarded to a project partner: 0.4 M€ |
| Eligible costs | Only the costs generated throughout the duration of the project can be eligible. Personnel (only ad hoc contracts/consultants/fellowships, max 50% of the requested fund);
- Travel costs and subsistence allowances (max 10% of the requested fund) only if associated with training activities linked to the project;
- Equipment (rent/leasing only, no limits), consumables (no limits), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund);
- Data handling and analysis (no limits);
- Overhead (maximum 10% of the requested fund).
- Transfer of eligible funds abroad for leasing, sub-contracts, etc. is not allowed
- Maximum funding per project: 250,000 Euros. In case that two eligible partners are involved in the Consortium, the total amount will be shared between the beneficiary Institutions |

---

Call Text 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR ACTION
<table>
<thead>
<tr>
<th><strong>Italy – It-MoH</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Italian Ministry of Health</strong></td>
<td><a href="http://www.salute.gov.it">www.salute.gov.it</a></td>
</tr>
</tbody>
</table>

Sub-contracts are not allowed except in case of absolute necessity and to fund the Italian PAOs (max. 10% of the requested total budget); the costs for sub-contracts need to be authorized by the It MoH in advance, following a detailed request. In this case, the pre-eligibility must be requested 20 working days before the deadline of the call.

**Additional documents required**
The Italian Ministry of Health will check for the pre-eligibility of the applicants before the submission of the pre-proposals to speed up the eligibility check process. To this end, it is mandatory that the applicants fill out and return a pre-eligibility check form (sent to all IRCCSs) through the IRCCS Scientific Directorate or ISS Directorate of Human and Economic Resources using the WFR System (Code ER) before the submission of their pre-proposals to the Joint Call Secretariat. The form, completed and duly signed, has to be returned at least 10 working days before the pre-proposal submission deadline. Applicants will receive a written notification of their eligibility status.

**Eligible One Health settings**
**Eligible institutions:**
Fundable: ONLY IRCCS that are the Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati)
Non fundable: University, research institute and other private and public research institute

**Eligible experimental approaches**
Check with national contact representatives

**Further information**
It-MoH follows the JPIAMR definition of ECR. The Italian ECR applicants have to send a declaration with the date of their PhD (including dates of maternity or military / civil service) using the WFR System (same Code ER). Researchers are not allowed to participate as PI/WP Leader in more than one 2023 call launched in the framework of different transnational calls (ERANET and/or other European Joint Actions and/or MAECI EPs) funded by the It MoH. MAXIMUM TWO PARTNERS funded by the It-MoH PER PROJECT (No more than two partners from the same country are allowed per project).

Researchers are requested to indicate the IRCCS as unique affiliated Institution and to use exclusively the IRCCS’s email.

Publications generated by the research activities must report the acknowledgements to the GRANT received by the IT MoH and the reference to the European Programme.
### Italy – FRRB

**Fondazione Regionale per la Ricerca Biomedica**

<table>
<thead>
<tr>
<th>Specific National/Regional rules</th>
<th>MAXIMUM TWO PARTNERS from Lombardy PER PROJECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible applicants:</td>
<td></td>
</tr>
<tr>
<td>1. Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care)</td>
<td></td>
</tr>
<tr>
<td>2. Public Health Care Providers (ASST)</td>
<td></td>
</tr>
<tr>
<td>3. Agenzie di Tutela della Salute (ATS),</td>
<td></td>
</tr>
<tr>
<td>4. Azienda Regionale Emergenza Urgenza (AREU),</td>
<td></td>
</tr>
<tr>
<td>5. Universities - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB</td>
<td></td>
</tr>
<tr>
<td>6. Research Institutes - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the definition of research institutes and organisations on the FRRB webpage https://www.frrb.it/it/jpiamr-jtc2023

All applicants must be located in Lombardy and their activities should take place in Lombardy.

Enterprises and for-profit Organisation are NOT eligible

#### Eligible costs

Direct costs:
- Personnel (for public IRCCS and ASST, ATS and AREU, ONLY staff recruited specifically on the project). Personnel costs of PIs who have a permanent contract (contratto indeterminato) with their own organisation are NOT eligible.
- Consumables, animals purchase, maintenance and breeding.
- Equipment (on hire or eligible amortization rate).
- Travel: max 10% of the total direct costs (overheads and subcontracting costs excluded)
- Publications (only open access): max 5% of the total direct costs (overheads and subcontracting costs excluded).
- Overheads: 20% flat rate calculated on direct costs (Subcontracting costs excluded from this calculation).
- Other direct costs: please include here other costs, including those related to patient involvement (insurance, reimbursement, etc.).
- Subcontracting: max 20% of the total direct costs (overheads costs excluded)

FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the “Subcontracting” category will be eligible up to a maximum of € 8.000.

Only costs generated over the lifetime of the project will be considered eligible.

#### Rules regarding the Principal Investigator (PI):

1. A Principal Investigator (PI) cannot simultaneously hold more than one FRRB grant. PIs who are currently FRRB grant holders cannot apply to a new JTC unless their project is closed before the deadline of the new JTC pre-proposals. A project is considered closed when the final financial and scientific reports have been sent to FRRB. This rule applies only to PIs, not to team members.
2. Personnel costs of PIs who have a permanent contract with their own organisation are **NOT** eligible
### Italy – FRRB
**Fondazione Regionale per la Ricerca Biomedica**

#### Additional documents required
It is not necessary to send the proposal to FRRB. However, FRRB requires a **Pre-eligibility form**. According to internal procedures, Regional Foundation for Biomedical Research (FRRB) will carry out an **eligibility check** to potential applicants prior to the submission of the pre-proposals.

The eligibility check will be based on the verification of a dedicated form ("**Pre-eligibility form**"), also available on the FRRB institutional website, to be returned, by email, to FRRB (progetti@frrb.it), duly completed and signed by the Principal Investigator at least 10 working days before the pre-proposal submission deadline.

FRRB will provide feedback on the "**Pre-eligibility form**", **ONLY** in case of major non-eligibility issues.

Principal Investigators (PIs) who submit a proposal without sending the "**Pre-eligibility form**" to FRRB beforehand will be automatically excluded.

In addition, FRRB provides an excel sheet to help applicants abide by FRRB funding rules. This form is meant to support the PIs in the elaboration of the proposal budget, but it does not need to be sent to FRRB.

Information and instructions on how to fill the Pre-Eligibility check form will be published on the dedicated webpage [https://www.frrb.it/it/jpiamr-jtc2023](https://www.frrb.it/it/jpiamr-jtc2023)

Following the award, Lombardy beneficiaries will be requested to submit annual scientific and financial reports.

<table>
<thead>
<tr>
<th>Eligible One Health settings</th>
<th>Only Human Health area will be eligible for funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible experimental approaches</td>
<td>Biomedical research ONLY in human settings. In case of clinical studies, the size and the duration should be compatible with the project timeline - studies should be completed by the end of the project.</td>
</tr>
<tr>
<td>Further information</td>
<td>Maximum € 500,000 per project (if there are two Lombardy partners in the same consortium, the amount of 500,000 will be shared)</td>
</tr>
</tbody>
</table>

### Lithuania – LMT
**Research Council of Lithuania**

#### Specific National/Regional rules
Please refer to the document following the link: [https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr](https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr)

The limit for the grant amount per project: up to 100K€ for consortium partner or up to 150K€ for coordinator/2 eligible Lithuanian partners in the consortium

#### Eligible applicants
Eligible for funding institutions are Lithuanian research and higher education institutions included in the Register of Education and Research institutions and public healthcare institutions. Beneficiary institution manage the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable ‘project partner’ means public or private legal entity that, together with the eligible institution, created the conditions for project implementation).

#### Eligible costs
Only costs generated during the lifetime of the project, related to project are eligible: staff, travel, consumables, subcontracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 20% from the direct costs).
### Lithuania – LMT
Research Council of Lithuania

<table>
<thead>
<tr>
<th>Additional documents required</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible One Health settings</td>
<td>All</td>
</tr>
<tr>
<td>Eligible experimental approaches</td>
<td>All</td>
</tr>
</tbody>
</table>
The beneficiary institution employs the principal investigator to work in the project and his workload must be at least 20 hours multiplied by the number of months to execute the project. Hourly rates approved by the Chairman of the Lithuanian Research Council must be applied for the personnel costs. All other general rules for competitive funding of Research Council of Lithuania apply: |

### Moldova – ANCD
Agentia Nationala pentru Cercetare si Dezvoltare

<table>
<thead>
<tr>
<th>Specific National/Regional rules</th>
<th>Government Decision 382/2019 regarding the Methodology for financing projects in the fields of research and innovation.</th>
</tr>
</thead>
</table>
| Eligible costs | a) the remuneration of the staff who are part of the research team, in compliance with the limits provided by the legislation in the budgetary sector and the related normative framework - up to 80%, including the taxes paid by the employer;  
*note*: scientific researchers indicated for remuneration from the state budget, will take into account not to exceed the 1.5 work rate in the projects financed by the Agency.  
b) procurement of raw materials, consumables, including reagents, animals, laboratory inventory necessary to carry out experiments for the purpose of realizing the project - up to 50%;  
c) the organization of scientific events (conferences, seminars, symposia, workshops, etc.) during the duration of the project - up to 10%;  
d) business trips abroad and in the country according to normative acts - up to 20%;  
e) editing and publishing monographs, scientific articles, scientific magazines, including the publication fee - up to 10%;  
f) services related to the project (experimental and production works) - up to 50%.  
Other: Established by the Government Decision 382/2019 |

<table>
<thead>
<tr>
<th>Additional documents required</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible One Health settings</td>
<td>Eligible</td>
</tr>
<tr>
<td>Eligible experimental approaches</td>
<td>Eligible</td>
</tr>
<tr>
<td>Further information</td>
<td>No</td>
</tr>
</tbody>
</table>
| **Specific National/Regional rules** | Only research organisations according to EC Framework for State aid for research and development and innovation (2014/C 198/01) are eligible for funding.  
See: [https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29](https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29)  
**Note:** A limited part of the requested national budget can be used for outsourcing. Otherwise, parties other than mentioned above can only participate as a non-funded partner, and need to secure their own funding in order to be involved in a project.  
ZonMw will avoid double funding and will not finance projects or part of projects that have been funded through other calls. ZonMw will cross-check the proposals submitted to ZonMw through the national and international calls for possible demands of double funding.  
You can only take part in one consortium within this call, either as coordinator or partner. |
| **Eligible costs** | Relevant project expenses, such as:  
− Salary-related costs  
− Travel costs  
− Direct running costs  
− Dissemination and knowledge exchange costs  
− Data management / data steward  
− Open access costs with a maximum of € 5000,- per project  
There will be a maximum of € 250.000 per consortium available (1 Dutch participant in the consortium: max. € 250.000, 2 Dutch participants in the consortium: max. € 250.000 for the both of them together).  
The ZonMw Grant Terms and Conditions are applicable. See: [https://www.zonmw.nl/en/news-and-funding/funding/grant-conditions-and-fineses/](https://www.zonmw.nl/en/news-and-funding/funding/grant-conditions-and-fineses/) |
| **Additional documents required** | Awarded projects will need to deliver a Consortium Agreement and Data Management Plan. With regards to the Consortium Agreement ZonMw requests an unsigned copy of the CA before the start of the project and a copy of the CA, signed by all partners, within 12 months after the project start date. |
| **Eligible One Health settings** | As described in the call text. |
| **Eligible experimental approaches** | As described in the call text. |
| **Further information** | − ZonMw will also fund Social Sciences.  
− In case the joint proposal is recommended for funding, Dutch applicants will have to submit a formal application through MijnZonMw.  
− Awards will be subject to standard ZonMw Grants Conditions.  
− All publications resulting from scientific research wholly or partly funded by ZonMw must immediately be made available in Open Access (without embargo), in accordance with the ZonMw Open Access policy. ZonMw accepts various Open Access routes. In addition to articles, ZonMw encourages recipients to make other types of scientific publications available in Open Access.  
− Make sure to consult the ZonMw Open Access publication and Data management policies. |
<table>
<thead>
<tr>
<th>Poland – NCN</th>
<th>National Science Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Specific National/Regional rules</strong></td>
<td>National rules for participation are given in the UNISONO resolution no. 28/2022 of 2 March 2022</td>
</tr>
<tr>
<td></td>
<td>Please note:</td>
</tr>
<tr>
<td></td>
<td>• project tasks to be carried out by Polish research teams may involve only basic research i.e. experimental or theoretical endeavours undertaken to gain new knowledge of the foundations of phenomena and observable facts, without any direct commercial use;</td>
</tr>
<tr>
<td></td>
<td>• If two or more different Polish institutions apply as partners within one international project consortium and seek funding from the NCN, they must apply to the NCN as a group of entities</td>
</tr>
<tr>
<td></td>
<td>• proposals may include application for state aid, except where a natural person applies for funding;</td>
</tr>
<tr>
<td></td>
<td>• proposals may involve non-commercial clinical trials related to a medicinal product or a medical device;</td>
</tr>
<tr>
<td></td>
<td>NCN funds projects that last either 24 or 36 months.</td>
</tr>
<tr>
<td><strong>Eligible costs</strong></td>
<td>All costs relevant, necessary and directly connected to the proposed research project including:</td>
</tr>
<tr>
<td></td>
<td>1. Personnel costs – permanent and/or temporary; including post-doc</td>
</tr>
<tr>
<td></td>
<td>2. Salaries and scholarships for PhD students;</td>
</tr>
<tr>
<td></td>
<td>3. Equipment: up to 500,000 PLN per unit;</td>
</tr>
<tr>
<td></td>
<td>4. Other direct costs: materials, devices and software, outsourcing and subcontracting, travel and subsistence costs, visits and consultations, collective investigators;</td>
</tr>
<tr>
<td></td>
<td>5. Overheads/indirect costs: there are two types of indirect costs, both calculated automatically:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General indirect costs include administrative personnel costs as well as costs of organizing conferences, workshops, seminars or meetings.</td>
</tr>
<tr>
<td></td>
<td>The amount budgeted for indirect costs may not be increased during the course of a research project.</td>
</tr>
<tr>
<td><strong>Additional documents required</strong></td>
<td>At the pre-proposal stage applicants must consult the Polish team’s budget table with NCN project officers no later than 1 March 2023.</td>
</tr>
<tr>
<td></td>
<td>At the full proposal stage, applicants must submit their national proposals in the Polish submission system (OSF).</td>
</tr>
<tr>
<td></td>
<td>National proposals must state the budgets in Polish currency using the conversion rate of 1 EUR = 4,7244 PLN.</td>
</tr>
<tr>
<td><strong>Eligible One Health settings</strong></td>
<td>As described in the call text.</td>
</tr>
<tr>
<td><strong>Eligible experimental approaches</strong></td>
<td>As described in the call text.</td>
</tr>
<tr>
<td><strong>Further information</strong></td>
<td>See national call texts in Polish and English for all national requirements.</td>
</tr>
<tr>
<td>Specific National/Regional rules</td>
<td>SAMRC Terms and Conditions of funding apply. See link below. Eligibility criteria:</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>− South African citizens or permanent residents from South African universities and other public and not-for-profit research organizations are eligible to apply.</td>
</tr>
<tr>
<td></td>
<td>− South African SMEs are eligible for funding as co-applicants. South African SMEs are eligible to apply as lead applicants provided that they have a South African academic partner as a collaborator.</td>
</tr>
<tr>
<td></td>
<td>− Principal investigators may only submit one application each as the principal investigator, but may be involved in more than one application if listed as a co-investigator.</td>
</tr>
<tr>
<td>Eligible costs</td>
<td>• Personnel: Soft-funded posts for individuals working on the project (e.g. post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided and they are not already funded from other means.</td>
</tr>
<tr>
<td></td>
<td>• Consultants: These may include both local and/or foreign consultants who provide a service or capability that is not available among the project partners but is essential for the completion of project deliverables.</td>
</tr>
<tr>
<td></td>
<td>• Equipment: Partial or full support for the cost of equipment may, in some instances, be requested, provided that it is directly required for the project. A budget limitation may apply.</td>
</tr>
<tr>
<td></td>
<td>• Supplies, consumables and other direct laboratory or research costs.</td>
</tr>
<tr>
<td></td>
<td>• Sub-contracts: These may be to any local or international organization that provides a service or capability that is not available among the project partners but is essential for the completion of project deliverables.</td>
</tr>
<tr>
<td></td>
<td>• Travel and accommodation that is directly related to the execution of the project.</td>
</tr>
<tr>
<td></td>
<td>• Institutional overhead: An indirect costs rate of 5% to a maximum of R250k per year (or any revised indirect costs rate specified by the SAMRC from time to time) is allowed on selected Non-eligible costs include:</td>
</tr>
<tr>
<td></td>
<td>• Salaries of permanent or fixed term staff, e.g. tenured staff, professors, etc., that are fully covered by the host institutions.</td>
</tr>
<tr>
<td></td>
<td>• Purchase or construction of a building.</td>
</tr>
<tr>
<td></td>
<td>• Rental costs for space that is owned by the institutions participating in the project.</td>
</tr>
<tr>
<td></td>
<td>• Recruitment or retrenchment costs for staff.</td>
</tr>
<tr>
<td></td>
<td>• Purchase of office furniture.</td>
</tr>
<tr>
<td>Additional documents required</td>
<td>− Approval of the application by the host institution is required.</td>
</tr>
<tr>
<td></td>
<td>− At the full proposal stage South African applicants may be required to submit more information which may include personal information and a separate budget table on a template to be provided by the SAMRC. Should personal information be provided, the SAMRC will process such information in accordance with the provisions of the Protection of Personal Information Act 4 of 2013 (POPIA) and any other privacy related legislation.</td>
</tr>
</tbody>
</table>
### South Africa – SAMRC

**South African Medical Research Council**

<table>
<thead>
<tr>
<th>Eligible settings</th>
<th>Projects addressing human health will be eligible for funding. SAMRC will NOT be funding projects on animal health and/or environment that do not include human health research activities.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible experimental approaches</td>
<td>All experimental approaches are eligible</td>
</tr>
<tr>
<td>Further information</td>
<td>SAMRC Terms and Conditions of Funding available here: <a href="https://www.samrc.ac.za/sites/default/files/attachments/2021-04-14/SAMRC%20Terms%20and%20Conditions%20of%20Funding.pdf">https://www.samrc.ac.za/sites/default/files/attachments/2021-04-14/SAMRC%20Terms%20and%20Conditions%20of%20Funding.pdf</a></td>
</tr>
</tbody>
</table>

### Spain – ISCIII

**National Institute of Health Carlos III**

| Specific National/Regional rules | Funding Program: Acción Estratégica en Salud 2023 (AES 2023)  
Initial funding pre-commitment: 500,000 €  
Number of proposals that could be funded: 2-3  
Projects’ duration: from 24 months to 36 months  
Maximum funding per awarded Spanish project partner:  
• Up to 180,000 € per partner (overheads included)  
• Up to 260,000 € per coordinator (overheads included)  
Eligible institutions:  
• Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Accredited according to the RD 339/2004, of February 27th or RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/2002, of December 26th). See the list of IIS in [this link](#).  
• Hospitals, primary health care or public health administration of the Spanish National Health System (SNS). These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes may be submitted).  
• CIBER. Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a Hospital, primary health care or public health administration of the SNS or IIS). Please contact Cristina Rodríguez ([cristina.rodriguez@ciberisciii.es](mailto:cristina.rodriguez@ciberisciii.es)) for more information related to CIBER’s eligibility.  
• Applicants from ISCIII are eligible. Eligibility criteria from AESI 2023 apply.  
• Public Universities  
• Private health entities and institutions, Public Research Institutions (OPIs) as defined in the article 47 of Law 14/2011, in accordance with the provisions of RD 202/2021, private universities with proven R&D activity capacity, other public R&D centres. These entities can only participate if they apply together with hospitals, primary health care or public health settings of the SNS, or IIS in the same proposal. It is not allowed to apply independently, thus there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.  
• Note: Same beneficiary institution cannot participate with more than one partner in the same project proposal. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

---

Call Text 16th JPIAMR transnational call for research projects within the ERA-NET JPIAMR ACTION
Spain – ISCIII
National Institute of Health Carlos III

- Please be careful that in AES2023 some specific Institutions may be declared as ineligible to receive funds by ISCIII in this call.
- Incompatibility for application to any other call are subject to the provisions in the relevant call.

**Eligibility of Principal Investigator (PI) and team members**

- PI can only participate in one project proposal per call.
- PIs belonging to any IIS should apply only from the IIS
- The PI and all members of the research group must belong to the eligible institutions or be affiliated to CIBER
- Only one PI per beneficiary institution may be funded within the same proposal.
- PIs that has an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the 31st December 2023 will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project.
- Incompatibility for application to any other call are subject to the provisions in the relevant call
- For additional incompatibilities please review AES2023

**Excluded personnel as PI**

- Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR).
- Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts).
- Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).
- Researchers contracted by a RICOR and platforms funded by ISCIII

**Eligible costs**

**Personnel costs:**

- It will be eligible personnel costs for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in AES2023 / ISCIII’s webpage.
- Contracts for PhD students will be done in the framework of National Subprogramme for Training, (scholarships are not eligible).
- Personnel costs will be eligible with a maximum of 36 PM in total for the personnel contracts altogether.
- The hiring of permanent personnel already belonging to the beneficiary entity or members of the research team will not be considered eligible expenses.

**Other eligible costs:** Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in AES 2023 that can be justified as necessary to carry out the proposed activities.

- **Overheads,** according to AES 2023 (25%)
- **Double funding of the same concept is not allowed**

**Eligible One Health settings**

- Human health. Animal health could be funded by ISCIII if the proposal is related with zoonotic diseases. Environment can only be funded if it has direct connection with human health.
### Spain – ISCIII
National Institute of Health Carlos III

#### Eligible experimental approaches

Spanish groups participating in a proposal performing a clinical study **must** include as members of the team personnel a member from the Clinical Trial Unit (Unidades de Investigación Clínica y Ensayos Clínicos - UICEC) belonging to the Clinical Research Supporting Platform of their institutions, the scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) and in absence of these personnel from UIC. In the proposals that performs a clinical study, it has to be specified in the proposal who is exactly the mandatory member of these dedicated Units.

#### Further information

**Additional requirements on data and repositories**

- Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "[ELIXIR Core Data Resources](https://elixir-europe.org/)", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).

- ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.

#### Submission of the proposal at the national level

- National applications will be required by ISCIII. Spanish Applicants should periodically check in the web page of ISCIII if they are qualified. ISCIII may not send invitations to the mandatory national phase.

- Due to administrative and legal regulations, the Institute of Health Carlos III establishes the **31st October 2023** as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII. The National application period will be stated in AES 2023. Any concerned applicant in a proposal for which no final decision has been made by the deadline could be declared not fundable by ISCIII or delayed their funding to the following year.

### Sweden – SIDA
Swedish International Development Cooperation Agency

#### Specific National/Regional rules

**Eligible institutions:** Sida will support the participation of researchers from least developed countries in sub-Saharan Africa (DAC List of ODA Recipients), and other sub-Saharan African countries where Sweden has bilateral development cooperation.

Institutions eligible to apply are Africa-based domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the following countries:

| **Sweden – SIDA**  
**Swedish International Development Cooperation Agency** | **Mauritania, Mozambique, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe**  
Profit-making organizations are **not** eligible to receive Sida funding within this initiative.** Eligible applicants:** African researchers employed by domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the countries specified above are eligible to apply.  
Researchers from profit-making organizations are **not** eligible to receive Sida funding within this initiative.  
Researchers may only be listed as a project coordinator or research partner on **one** project application. However, multiple submissions from multiple projects with researchers based at the same institution are allowed.  
**Eligible costs**  
Eligible costs include salaries, consumables, equipment, travel and indirect costs. The use of Sida funds to purchase vehicles, including motorbikes, is not permitted in the frame of this call. Requests for funding for equipment should be accompanied by a plan for the maintenance and repair of the equipment for the duration of the project.  
Grant funds may not be used to reimburse expenses incurred prior to the project start date.  
Sida will not fund projects or parts of projects that have been funded through other calls.  
No grantee is permitted to make sub-grants, but all grantees will be permitted to contract for services, up to a maximum of 20,000 Euro. Please be aware that this limit applies to funds paid by an awardee to any other organization (or an individual employed at another organization) as a subcontractor.  
Maximum budget per Sida partner is **250,000 Euro**, and up to **350,000 Euro** if the Sida partner is the coordinator of a proposal. A maximum of 2 partners eligible for Sida funding may request funding from Sida within a consortium.  
**Additional documents required**  
Grants to project coordinators/partners funded by Sida can only be administered by a university or other academic research institution.  
General conditions applicable to grants from Sida to NGO’s regarding project/programme support will apply to all institutions considered for a grant (please go to [https://www.jpiamr.eu/calls/diagnostics-surveillance-call-2023/](https://www.jpiamr.eu/calls/diagnostics-surveillance-call-2023/) to download the document).  
Before deciding on grant funding, the capacity of each applicant’s institution to administrate funds will be assessed according to Sidas regulations for contribution management, and the projects’ adherence to the Strategy for Sweden’s development cooperation in research for poverty reduction and sustainable development 2022–2028.  
**Eligible One Health settings**  
Human health, animal health and environmental health  
**Eligible experimental approaches**  
All |
### Sweden – SIDA
#### Swedish International Development Cooperation Agency

| Further information | For the purpose of grant management, Sida has partnered with a regional organization experienced in forwarding funding to African universities and research institutes. Individuals that are members of projects invited to make a full proposal may be required to submit additional information that pertains to their specific work and/or budget within the research consortium to Sida, or a designated partner organization. |

### Sweden – SRC
#### Swedish Research Council

<table>
<thead>
<tr>
<th>Specific National/Regional rules</th>
<th>The applicant must be an individual researcher holding a PhD. Only researchers at an administrating organisation approved by the Swedish Research Council may apply. Please refer to general applicant eligibility requirements found <a href="#">here</a>. The applicant may not have an ongoing JPIAMR project grant, or any other project grant concerning the same project concept, funded by the Council, at the start of the grant period. All Swedish applicants are encouraged to communicate with the JPIAMR national contact person regarding their intention to participate in the call, before submission of the consortium application. Grant amount: Max. 3 500 000 SEK (approx. 320 000 Euro) per consortium with max 2 Swedish partners. Min. 1 200 000 SEK (approx. 110 000 Euro) per partner. Max 5 000 000 SEK (approx. 457 000 Euro) if a Swedish participant is the coordinator of the consortium. No funding of industrial partners. Use the exchange rate of 1 Euro = 10,94 SEK to calculate actual grant amounts for the application. You can only take part in one consortium within this call, either as coordinator or partner. All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application using the Swedish Research Council’s application system Prisma. The application form in Prisma can be reached from the national call text at the SRC website. Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the Prisma call may result in the Swedish partner being declared ineligible.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible costs</td>
<td>The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person’s activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs. Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.</td>
</tr>
<tr>
<td>Additional documents required</td>
<td>A parallel application must be submitted in the SRC’s application system Prisma. See above.</td>
</tr>
<tr>
<td>Eligible One Health settings</td>
<td>All one health settings are eligible.</td>
</tr>
</tbody>
</table>
### Sweden – SRC
#### Swedish Research Council

<table>
<thead>
<tr>
<th>Eligible experimental approaches</th>
<th>No particular conditions.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Further information</td>
<td>See national call texts in Swedish and English for all national requirements.</td>
</tr>
</tbody>
</table>

### Switzerland – SNSF
#### Swiss National Research Foundation

| Specific National/Regional rules | Projects must comply with SNSF Project Funding regulations and practices:  
|----------------------------------|--------------------------------------------------------------------|
|                                  | • SNSF Funding regulations  
|                                  | • SNSF Project Funding regulations  
|                                  | • General implementation regulations for the Funding Regulations |

In particular, all Swiss based applicants and co-applicants seeking SNSF support must be eligible for SNSF Project Funding. Please note that applications submitted by a non-eligible person will not be considered nor evaluated. Please refer to the regulations and contact the national contact person for questions and reassurance.

Article 7.3 of the Regulations on project funding applies. Swiss based applicants may participate in at most one proposal within this call.

Partners of the international project consortium applying for funding at other funding agencies than the SNSF cannot be declared as project partners in the sense of article 11.2 of the SNSF Funding Regulations. They should be declared as consortium partners instead and apply for their funding at their respective research funding organisation.

Article 17 of the SNSF Funding Regulations only applies in the sense that proposals with overlapping funding periods are only approved if the research projects pursue different goals in the context of this European programme than any ongoing projects by the same applicant.

Grants will be managed according to standard SNSF rules. Yearly financial reports for the use of SNSF funds and a scientific report at the end of the project will be required.

| Eligible costs | According to the regulations on project funding (article 8).
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Overhead contributions cannot be applied for. They are calculated on the basis of the total research funding given to a particular institution through all SNSF funding instruments, are paid directly to the applicant’s institution on a yearly basis.</td>
</tr>
<tr>
<td></td>
<td>The SNSF exclusively funds research conducted for purposes that are not directly commercial. Pursuant to the Research and Innovation Promotion Act RIPA and the legal framework of the SNSF, no research grants are awarded if the relevant research is conducted for directly commercial purposes or if the persons involved in the research work are not scientifically independent.</td>
</tr>
</tbody>
</table>

| Additional documents required | Swiss based partners must provide basic administrative data by submitting administrative applications via the online submission system mySNF for the same deadlines as the consortium applications. For this, Swiss based partners need a personal account on www.mySNF.ch. Please note that the SNSF defined a new format for the CV and Swiss applicants also need an account in the SNSF Portal to create their CV in the required standardised format. Please select the “Project funding->Partnerships->JPI AMR” funding instrument when creating the administrative application for the pre- |
### Switzerland – SNSF
**Swiss National Research Foundation**

| proposal and if you are invited to submit a proposal for the second stage. The pre-proposal can be used as a template when the full proposal is created in mySNF and should be referred to in the section “Relation to pre-proposal” of the full proposal. In case of funding, consortia including Swiss partners must submit a data management plan (DMP) on mySNF which complies with the SNSF policy on open research data. |

| Eligible One Health settings | All One Health settings including humans, animals, plants, and the environment |
| Eligible experimental approaches | No particular limitations |
| Further information | The SNSF earmarked a budget in order to finance approximately 2-3 projects with applicants from Switzerland. To provide for a greater degree of flexibility, there is no maximum contribution set per project for the Swiss part. Nevertheless, budgets of a collaborative research project must be balanced and the SNSF expects that applicants carefully consider the budgetary request in a relation to the effective needs of the project. If an international project includes more than one Swiss based applicant (Principal Investigator), then these applicants must apply together as a consortium and submit a joint budget. |

### United Kingdom – UKRI Innovate UK
**Innovate UK, UKRI**

| Specific National/Regional rules | This table contains information for those eligible for Innovate UK funding (For those eligible for UK Research Council funding please see the separate table below). Awards will be made through Innovate UK. Potential applicants are strongly advised to contact the National Call Secretariat, or the Innovate UK National contact as detailed in Annex A of the Call, in advance of making an application, to resolve any eligibility queries. The Innovate UK funded component of the JPIAMR consortium project is open to Innovate UK funded collaborations. |
| To be eligible for funding from Innovate UK, your organisation must be a UK registered micro, small or medium-sized enterprise (SME). |
| More information on the different types of organisation can be found in Innovate UK’s General Guidance. Subject to conditions of eligibility and peer review being fully met, up to €1 million will be available to UK SMEs for this call. Innovate UK anticipate supporting four applications. Applicants to Innovate UK funding, may request up to a maximum of €300,000 or 70% of project costs (whichever is lower), per application. |
| Once the highest scoring projects have been funded, the remaining Innovate UK funds may be allocated to projects scoring lower than projects requesting more than the remaining funds available. |
| Applicants who intend to collaborate with UK academic or other non-industrial partners should note that any costs incurred, direct or otherwise, by these partners cannot be met by Innovate UK. Academic partners should apply for funding via UKRI Research Councils (see the Research Councils table below for further eligibility information). |
### United Kingdom – UKRI Innovate UK

**Innovate UK, UKRI**

- Successful Innovate UK funded partners in transnational consortia will be required to submit an Innovate UK application. This must replicate the Innovate UK component of the JPIAMR application and will not be peer-reviewed. The Innovate UK funded partners must therefore identify which participant is the lead Innovate UK funded applicant, who will be responsible for submitting the Innovate UK Innovation Funding Service (IFS).
- Awards are subject to [Innovate UK funding rules](https://www.ukri.org/funding/how-to-apply/eligibility/). Award letters will include any additional terms and conditions specific to the call.

### Eligible costs

For full details on what costs you can claim see the Innovate UK [project costs guidance for non-academic organisations](https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/). Please see the [Innovate UK Guidance for Applicants](https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/) for full information of eligibility and resourcing of grants.

### Additional documents required

As well as the JPIAMR application form, applicants must also complete a Innovate UK Budget Proforma. Costs should be included in pounds sterling (GBP) on the UK budget proforma and included on the JPIAMR application form in Euros.

Applicants should include a statement on the Innovate UK budget proforma to confirm the exchange rate used, and that costs are entered according to standard [Innovate UK funding rules](https://www.ukri.org/funding/how-to-apply/eligibility/).

### Eligible One Health settings

Innovate UK will support One Health areas of research and innovation in section 2.2.

### Eligible experimental approaches

We will fund industrial research projects and experimental development projects, as defined in the Innovate UK [guidance on categories of research](https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/).

### Further information

For further details please refer to the [Innovate UK guidance for applicants](https://www.ukri.org/funding/how-to-apply/eligibility/).

---

### United Kingdom – UKRI Research Councils

**Specific National/Regional rules**

Awards will be made through MRC on behalf of three UKRI Councils: MRC, BBSRC and EPSRC. Potential applicants are strongly advised to contact the National Call Secretariat, or the UK National contact as detailed in Annex A of the Call, in advance of making an application, to resolve any eligibility queries.

- Applicants must be a UK based Higher Education Institution, Research Organisation or NHS body, eligible to receive UKRI funding. Industrial partners may not request costs. Full details of eligibility for Research Council funding can be found on the UKRI website: [https://www.ukri.org/funding/how-to-apply/eligibility/](https://www.ukri.org/funding/how-to-apply/eligibility/)
- Please see the UKRI Guidance for Applicants for full information of eligibility and resourcing of grants [https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/](https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/)
- Please note grant applications with UK partners may be shared in full with Veterinary Medicines Directorate and Food Standards Agency
- For the purposes of this call, a ‘partner’ requesting funding from UKRI is a legal entity. Multiple researchers from the same legal entity form
**United Kingdom – UKRI Research Councils**

- a single partner, but only one of these researchers should be named on the JPIAMR application form.
- The UK component of applications should use full economic costings (fEC). The total amount requested must be the 80% fEC value. The submitting organisations must agree to find the balance of fEC for the project from other resources. In the ‘financial plan’ section of the JPIAMR application form, the ‘sum requested’ is the 80% fEC amount. The ‘total’ is the 100% fEC amount plus any further resources or in-kind contributions.
- Subject to conditions of eligibility and peer review being fully met, up to €2M will be available to UK researchers for this call. In addition, up to €230,000 from the Veterinary Medicines Directorate will be available for proposals relevant to animal diagnostics. UKRI anticipate supporting 8 applications. Individual consortia may request up to a maximum of €400 000 UK funding, per application. This maximum amount refers to the 80% fEC value and not the 100% fEC value.
- Once the highest scoring projects have been funded, the remaining UKRI funds may be allocated to projects scoring lower than projects requesting more than the remaining funds available.
- Applicants who intend to collaborate with industrial or other non-academic partners should note that any costs incurred, direct or otherwise, by these partners cannot be met by UKRI Research Councils and that these partners should apply for funding via Innovate UK.
- Successful UK partners in transnational consortia will be required to upload a single application to Je-S within one month of the notice of award. This must replicate the UKRI component of the JPIAMR application and will not be peer-reviewed. A single UKRI award will be issued to all UK partners within a consortium. The UK partners must therefore identify which researcher is the lead UK applicant, who will be responsible for submitting the Je-S application and whose institution will be responsible for disbursing UKRI funds to any other UKRI-funded partners.
- Awards are subject to [UKRI Terms and Conditions](#) for funding. Award letters will include any additional terms and conditions specific to the call.

### Eligible costs

Eligible costs include project-related costs incurred after the award start date, including:

- Principal Investigators and Co-Investigators time
- Research and technical staff
- Estates and Indirect costs
- Animal costs
- Travel and Subsistence
- Equipment
- Consumables
- Recruitment and advertising costs for staff directly employed on the project
- Costs related to research data management
- NHS Research costs.

Ineligible costs include:
### United Kingdom – UKRI Research Councils

- NHS support and NHS treatment costs
- PhD students
- Publication costs, including open access publication costs.
- Industrial partners

For more information regarding eligible costs, please see the [MRC Guidance for Applicants](#).

### Additional documents required

As well as the JPIAMR application form, applicants must also complete a UK Budget Proforma.

Costs should be included in pounds sterling (GBP) on the UK budget proforma (which can be downloaded from the call entry in the Funding Finder on UKRI’s website) and included on the JPIAMR application form in Euros using an exchange rate of £1:€1.15. Applicants should include a statement on the UK budget proforma to confirm the exchange rate used, and that costs are entered at 80% fEC according to standard Research Council funding policy.

Applications that incur excess treatment costs for studies involving patients will be required to complete a SoECAT form if invited for a full application. Please see the [MRC Guidance for Applicants](#) for further information.

### Eligible One Health settings

UKRI is unable to support all research areas within the scope of this call because only MRC, BBSRC and EPSRC are contributing funds.

For this call, UKRI is unable to support applications where the UK research component relates to wild animals or wild plants.

Applications with a major focus on arts, humanities and social sciences approaches, or the natural environment will not be eligible for funding.

### Eligible experimental approaches

All experimental approaches, including in vitro, in silico and in vivo pre-clinical, phase I or IIA clinical trials are eligible for funding.

### Further information

For further details please refer to the [MRC Guidance for Applicants](#).